Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
78.4 (1y: +21%)
Market Cap 17.43 B P/E(ttm)
Enterprise Value 16.88 B P/B 16.90
VRTX- NAS (USA)
Vertex Pharmaceuticals
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$78.40
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry		 vs
history
Cash to Debt 1.896
VRTX's Cash to Debt is ranked lower than
71% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 46.63 vs. VRTX: 1.896 )
VRTX' s 10-Year Cash to Debt Range
Min: 1.11   Max: 23.05
Current: 1.9
1.11
23.05
Equity to Asset 0.11
VRTX's Equity to Asset is ranked lower than
83% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. VRTX: 0.11 )
VRTX' s 10-Year Equity to Asset Range
Min: -0.02   Max: 0.9
Current: 0.11
-0.02
0.9
Interest Coverage 0.2
VRTX's Interest Coverage is ranked lower than
63% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 37.90 vs. VRTX: 0.2 )
VRTX' s 10-Year Interest Coverage Range
Min: 0   Max: No Debt
Current: 0.2
F-Score: 2
Z-Score: 4.58
M-Score: -3.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry		 vs
history
Operating margin (%) 0.20
VRTX's Operating margin (%) is ranked higher than
62% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -31.50 vs. VRTX: 0.20 )
VRTX' s 10-Year Operating margin (%) Range
Min: -602.6   Max: 8.1
Current: 0.2
-602.6
8.1
Net-margin (%) -7
VRTX's Net-margin (%) is ranked higher than
59% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -29.90 vs. VRTX: -7 )
VRTX' s 10-Year Net-margin (%) Range
Min: -630.3   Max: 2.1
Current: -7
-630.3
2.1
ROE (%) -10.7
VRTX's ROE (%) is ranked lower than
52% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. VRTX: -10.7 )
VRTX' s 10-Year ROE (%) Range
Min: -469.1   Max: 3.8
Current: -10.7
-469.1
3.8
ROA (%) -3.9
VRTX's ROA (%) is ranked higher than
58% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. VRTX: -3.9 )
VRTX' s 10-Year ROA (%) Range
Min: -65.1   Max: 1.3
Current: -3.9
-65.1
1.3
ROC (Joel Greenblatt) (%) 0.80
VRTX's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VRTX: 0.80 )
VRTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -600.5   Max: 110.3
Current: 0.8
-600.5
110.3
Revenue Growth (%) 86.9
VRTX's Revenue Growth (%) is ranked higher than
98% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VRTX: 86.9 )
VRTX' s 10-Year Revenue Growth (%) Range
Min: -25.4   Max: 86.9
Current: 86.9
-25.4
86.9
EPS Growth (%) -39.4
VRTX's EPS Growth (%) is ranked lower than
96% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VRTX: -39.4 )
VRTX' s 10-Year EPS Growth (%) Range
Min: -39.4   Max: 36.8
Current: -39.4
-39.4
36.8
» VRTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

VRTX Guru Trades in Q2 2012

Jim Simons 282,217 sh (New)
Daniel Loeb 500,000 sh (New)
Joel Greenblatt 20,025 sh (New)
John Burbank 200,000 sh (New)
Jean-Marie Eveillard Sold Out
Paul Tudor Jones Sold Out
John Hussman Sold Out
Pioneer Investments 2,706,966 sh (-5.23%)
Vanguard Health Care Fund 2,243,700 sh (-15.13%)
George Soros 112,000 sh (-44%)
Steven Cohen 158,822 sh (-64.19%)
NWQ Managers 188,842 sh (-83.86%)
» More
Q3 2012

VRTX Guru Trades in Q3 2012

Daniel Loeb 700,000 sh (+40%)
NWQ Managers 207,963 sh (+10.13%)
Vanguard Health Care Fund 2,243,700 sh (unchged)
George Soros Sold Out
Jim Simons Sold Out
Joel Greenblatt Sold Out
Pioneer Investments 2,694,928 sh (-0.44%)
John Burbank 150,000 sh (-25%)
Steven Cohen 77,662 sh (-51.1%)
» More
Q4 2012

VRTX Guru Trades in Q4 2012

Louis Moore Bacon 199,701 sh (New)
NWQ Managers 249,530 sh (+19.99%)
Vanguard Health Care Fund 2,243,700 sh (unchged)
Daniel Loeb Sold Out
Steven Cohen Sold Out
John Burbank Sold Out
Pioneer Investments 2,438,596 sh (-9.51%)
» More
Q1 2013

VRTX Guru Trades in Q1 2013

Jim Simons 137,417 sh (New)
Andreas Halvorsen 780,500 sh (New)
Steven Cohen 13,529 sh (New)
Vanguard Health Care Fund 2,489,800 sh (+10.97%)
Louis Moore Bacon Sold Out
Pioneer Investments 2,422,523 sh (-0.66%)
NWQ Managers 191,032 sh (-23.44%)
» More
» Details

Insider Trades

Latest Guru Trades with VRTX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Daniel Loeb 2012-12-31 Sold Out 0.77%$38.88 - $59.42 $ 78.470%0
John Burbank 2012-12-31 Sold Out 0.38%$38.88 - $59.42 $ 78.470%0
Daniel Loeb 2012-09-30 Add 40%0.22%$48.38 - $59.07 $ 78.446%700000
George Soros 2012-09-30 Sold Out 0.09%$48.38 - $59.07 $ 78.446%0
John Burbank 2012-09-30 Reduce -25%0.09%$48.38 - $59.07 $ 78.446%150000
Joel Greenblatt 2012-09-30 Sold Out 0.08%$48.38 - $59.07 $ 78.446%0
John Hussman 2012-06-30 Sold Out 0.93%$35.75 - $65.62 $ 78.454%0
Daniel Loeb 2012-06-30 New Buy0.85%$35.75 - $65.62 $ 78.454%500000
John Burbank 2012-06-30 New Buy0.38%$35.75 - $65.62 $ 78.454%200000
Joel Greenblatt 2012-06-30 New Buy0.08%$35.75 - $65.62 $ 78.454%20025
George Soros 2012-06-30 Reduce -44%0.05%$35.75 - $65.62 $ 78.454%112000
Jean-Marie Eveillard 2012-06-30 Sold Out 0.02%$35.75 - $65.62 $ 78.454%0
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Vertex Pharmaceuticals

Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC
December 16, 2012
According to GuruFocus updates, these stocks have declined the most since Gurus have bought. Read more...

Ratios

vs
industry		 vs
history
P/B 16.90
VRTX's P/B is ranked lower than
89% of the 359 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. VRTX: 16.90 )
VRTX' s 10-Year P/B Range
Min: 1.92   Max: 36.51
Current: 16.9
1.92
36.51
P/S 11.80
VRTX's P/S is ranked lower than
59% of the 391 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. VRTX: 11.80 )
VRTX' s 10-Year P/S Range
Min: 4.47   Max: 80.48
Current: 11.8
4.47
80.48
PFCF 137.50
VRTX's PFCF is ranked lower than
82% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 30.73 vs. VRTX: 137.50 )
VRTX' s 10-Year PFCF Range
Min: 12.84   Max: 1962
Current: 137.5
12.84
1962
EV-to-EBIT 16.9
VRTX's EV-to-EBIT is ranked lower than
92% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 21.21 vs. VRTX: 16.9 )
VRTX' s 10-Year EV-to-EBIT Range
Min: 18.4   Max: 4086.5
Current: 16.9
18.4
4086.5

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 142.5
VRTX's Price/Net Current Asset Value is ranked lower than
82% of the 313 Companies
in the Global Biotechnology industry.

( Industry Median: 41.90 vs. VRTX: 142.5 )
VRTX' s 10-Year Price/Net Current Asset Value Range
Min: 36.1   Max: 875.8
Current: 142.5
36.1
875.8
Price/Tangible Book 56
VRTX's Price/Tangible Book is ranked lower than
97% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 4.90 vs. VRTX: 56 )
VRTX' s 10-Year Price/Tangible Book Range
Min: 3.2   Max: 75.5
Current: 56
3.2
75.5
Price/Median PS Value 0.8
VRTX's Price/Median PS Value is ranked higher than
67% of the 345 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. VRTX: 0.8 )
VRTX' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 4.7
Current: 0.8
0.3
4.7
Forward Rate of Return (Yacktman) -1.78
VRTX's Forward Rate of Return (Yacktman) is ranked lower than
65% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VRTX: -1.78 )
VRTX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -7.5   Max: -3.4
Current: -1.78
-7.5
-3.4

Business Description

Vertex Pharmaceuticals was incorporated in Massachusetts in 1989. The Company is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. The Company's two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus, or HCV, infection; and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis, or CF, who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. The Company has ongoing clinical programs involving drug candidates intended for the treatment of HCV infection, CF, rheumatoid arthritis, influenza and epilepsy. Its HCV clinical programs are focused on developing all-oral, interferon-free combinations of HCV drugs and drug candidates that have the potential to further improve treatment options available to patients with HCV infection. In its CF program, the Company is investigating the use of ivacaftor as a monotherapy in additional populations of patients with CF and combinations of ivacaftor and other CF drug candidates. As the Company markets and sells its approved products and advances its drug candidates through clinical development toward commercialization, it continues to build and maintain its supply chain and quality assurance resources. The Company currently relies on an international network of third parties to manufacture and distribute its drug candidates for clinical trials. The Company faces competition based on the safety and efficacy of its products, the timing and scope of regulatory approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent protection and other factors. The Company's competitors are Abbott Laboratories, Achillion Pharmaceuticals, Inc., Boehringer Ingelheim, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Hoffman-La Roche, Idenix Pharmaceuticals, Inc. and Jansse. The research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record keeping, promotion, advertising, distribution and marketing of its products and drug candidates are subject to extensive regulation by United States and foreign governmental authorities.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:VX1.Germany
» More Articles for VRTX

Headlines

Articles On GuruFocus.com
Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 
Idenix Pharmaceuticals Lagging Behind in Breakthrough Hepatitis C Drug Development Jul 13 2012 
Weekly Top Insider Sells: GMCR, VRTX, CERN, and AGN May 14 2012 
Idenix: Strong Pipeline Will Reward Investors Apr 24 2012 
Columbia Management Fourth Quarter Letter with Comments on SWK, AGCO, CE, MCP, VRTX, DOLE, F, HAS, A Apr 10 2012 
Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
4 Pharmaceuticals with Long and Short Opportunities Feb 28 2012 
Hussman Fund Q4 Portfolio Overview Feb 02 2012 
John Hussman’s Biggest Fourth-Quarter Buys Jan 31 2012 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial